Abstract
In patients with newly diagnosed glioblastoma multiforme (GBM), concurrent chemo-radiotherapy with temozolomide is the new standard of care. In the present phase I study we investigated the association of gemcitabine, a cell-cycle antimetabolite with radiosensitizing properties, with radiotherapy (RT) in the first line treatment. Gemcitabine was delivered at a fixed dose-rate of 10 mg/m2/min weekly for 6 weeks starting 24–72 h prior to, and then concomitantly with RT (2.0 Gy per fraction, total dose 60 Gys). The primary end-point was the identification of dose-limiting toxicity (DLT), and maximum tolerated dose (MTD). Planned dose levels of gemcitabine started from 200 mg/m2/weekly (level 1), with sequential dose escalations of 25 mg/m2. Ten patients were enrolled, all with evaluable disease after surgery. Six patients were male, median age was 55 years (44–75), and median baseline Karnofsky performance status was 85 (70–100). Four patients entered level 1, one patient being excluded from the study because of early disease progression. At this level, two of three patients developed progressive neurological deterioration, potentially related to the experimental treatment. On this basis gemcitabine dose was prudentially reduced to 175 mg/m2/weekly in the subsequent step (level −1). No DLT was encountered in the six patients enrolled at this level. Interestingly, at this dose only two grade three toxicities (one neutropenia and one raise in serum transaminases) were reported. Thus, fixed dose-rate gemcitabine at 175 mg/m2/weekly is the recommended regimen for further evaluation in a phase II study that is presently in progress.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
Lawrence TS, Blackstock AW, McGinn C (2003) The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 13:13–21
Crinò L, Scagliotti GV, Ricci S et al (1999) Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17:3522–3530
Eckel F, Schneider G, Schmid RM (2006) Pancreatic cancer: a review of recent advances. Expert Opin Investig Drugs 15:1395–1410
von der Maase H (2001) Gemcitabine-containing regimens in bladder cancer: a new standard of care. Semin Oncol 28(suppl):1–3
Lund B, Kristjansen PE, Hansen HH (1993) Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 19:45–55
Plunkett W, Huang P, Xu YZ, et al (1995) Gemcitabine: metabolism, mechanism of actions and self-potentiation. Semin Oncol 22(suppl):3–10
Abbruzzese JL, Grunewald R, Weeks EA et al (1991) A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491–498
Grunewald R, Kantarjian H, Keating MJ et al (1990) Pharmacologically directed design of the dose-rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukaemia. Cancer Res 50:6823–6826
Tempero M, Plunkett W, Ruiz Van Haperen V et al (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402–3408
Ceribelli A, Gridelli C, De Marinis F et al (2003) Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. Cancer 98:337–343
Shewach DS, Hahn TM, Chang E et al (1994) Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 54:3218–3223
Milas L, Fuji T, Hunter N et al (1999) Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 59:107–114
Maraveyas A, Sgouros J, Upadhyay S et al (2005) Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study. Br J Cancer 92:815–819
Kleihues P, Cavenee WK (eds) (2000) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon
National Cancer Institute. Common toxicity criteria version 3.0. Available at http://ctep.cancer.gov/forms/CTCAEv3.pdf Cited 23 February 2007
Macdonald DR, Cascino TL, Schold SC Jr et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280
Brazil L, Thomas R, Laing R et al (1997) Verbally administered Barthel Index as functional assessment in brain tumour patients. J Neurooncol 34:187–192
Crowley J (ed) (2001) Handbook of statistics in clinical oncology. Marcel Dekker, New York
Curran WJ (2002) New chemotherapeutic agents: update of major chemoradiation trials in solid tumors. Oncology 63(suppl):29–38
Carpinelli G, Bucci B, D’Agnano I et al (2006) Gemcitabine treatment of experimental C6 glioma: the effects on cell cycle and apoptotic rate. Anticancer Res 26:3017–3024
Rieger J, Durka S, Streffer J et al (1999) Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone. Eur J Pharmacol 365:301–308
Weller M, Streffer J, Wick W et al (2001) Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. A phase II study. Cancer 91:423–427
Gertler SZ, MacDonald D, Goodyear M et al (2000) NCIC-CTG phase II study of gemcitabine in patients with malignant glioma. Ann Oncol 11:315–318
Eisbruch A, Shewach DS, Bradford CR et al (2001) Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol 19:792–799
Trodella L, Granone P, Valente S et al (2002) Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer. J Clin Oncol 20:804–810
Martin C, Lund B, Anderson H, Thatcher N (1996) Gemcitabine: once weekly schedule active and better tolerated than twice-weekly schedule. Anticancer Drugs 7:351–357
Acknowledgements
The Authors thank Eli-Lilly Corporation for providing gemcitabine, free of cost.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fabi, A., Mirri, A., Felici, A. et al. Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study. J Neurooncol 87, 79–84 (2008). https://doi.org/10.1007/s11060-007-9489-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-007-9489-x